196 related articles for article (PubMed ID: 34895284)
1. Tumor-stroma ratio as a new prognosticator for pseudomyxoma peritonei: a comprehensive clinicopathological and immunohistochemical study.
Ma R; Lin YL; Li XB; Yan FC; Xu HB; Peng Z; Li Y
Diagn Pathol; 2021 Dec; 16(1):116. PubMed ID: 34895284
[TBL] [Abstract][Full Text] [Related]
2. [Clinical evaluation of tumor-stroma ratio in pseudomyxoma peritonei from the appendix].
Ma R; Li XB; Yan FC; Lin YL; Li Y
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Apr; 52(2):240-246. PubMed ID: 32306005
[TBL] [Abstract][Full Text] [Related]
3. Pathological prognostic factors of pseudomyxoma peritonei: comprehensive clinicopathological analysis of 155 cases.
Yan F; Lin Y; Zhou Q; Chang H; Li Y
Hum Pathol; 2020 Mar; 97():9-18. PubMed ID: 31926211
[TBL] [Abstract][Full Text] [Related]
4. Preoperative carcinoembryonic antigen level predicts prognosis in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Canbay E; Ishibashi H; Sako S; Mizumoto A; Hirano M; Ichinose M; Takao N; Yonemura Y
World J Surg; 2013 Jun; 37(6):1271-6. PubMed ID: 23467926
[TBL] [Abstract][Full Text] [Related]
5. Validation of the Recent PSOGI Pathological Classification of Pseudomyxoma Peritonei in a Single-Center Series of 265 Patients Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
Baratti D; Kusamura S; Milione M; Bruno F; Guaglio M; Deraco M
Ann Surg Oncol; 2018 Feb; 25(2):404-413. PubMed ID: 29159742
[TBL] [Abstract][Full Text] [Related]
6. Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei Arising from Urachus.
Liu Y; Ishibashi H; Hirano M; Takeshita K; Mizumoto A; Ichinose M; Nishino E; Kashu I; Yamamoto Y; Sugarbaker PH; Yonemura Y
Ann Surg Oncol; 2015 Aug; 22(8):2799-805. PubMed ID: 25572681
[TBL] [Abstract][Full Text] [Related]
7. The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery.
Kusamura S; Barretta F; Yonemura Y; Sugarbaker PH; Moran BJ; Levine EA; Goere D; Baratti D; Nizri E; Morris DL; Glehen O; Sardi A; Barrios P; Quénet F; Villeneuve L; Gómez-Portilla A; de Hingh I; Ceelen W; Pelz JOW; Piso P; González-Moreno S; Van Der Speeten K; Deraco M;
JAMA Surg; 2021 Mar; 156(3):e206363. PubMed ID: 33502455
[TBL] [Abstract][Full Text] [Related]
8. Pseudomyxoma peritonei: biological features are the dominant prognostic determinants after complete cytoreduction and hyperthermic intraperitoneal chemotherapy.
Baratti D; Kusamura S; Nonaka D; Cabras AD; Laterza B; Deraco M
Ann Surg; 2009 Feb; 249(2):243-9. PubMed ID: 19212177
[TBL] [Abstract][Full Text] [Related]
9. [Pathological prognostic factors of pseudomyxoma peritonei].
Yan FC; Lin YL; Zhao HY; Zhou Q; Chang H; Li Y
Zhonghua Bing Li Xue Za Zhi; 2019 Jul; 48(7):543-549. PubMed ID: 31288310
[No Abstract] [Full Text] [Related]
10. Pre-operative tumour marker status predicts recurrence and survival after complete cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal Pseudomyxoma Peritonei: Analysis of 519 patients.
Taflampas P; Dayal S; Chandrakumaran K; Mohamed F; Cecil TD; Moran BJ
Eur J Surg Oncol; 2014 May; 40(5):515-520. PubMed ID: 24462284
[TBL] [Abstract][Full Text] [Related]
11. [A single-center clinical analysis of 65 cases of pseudomyxoma peritonei from appendiceal origin in the early stage].
Ma RQ; Xia A; Zhai XC; Chen F; Xu HB
Zhonghua Zhong Liu Za Zhi; 2019 Sep; 41(9):698-702. PubMed ID: 31550861
[No Abstract] [Full Text] [Related]
12. [Prognostic value of clinical and pathological characteristics in 48 women with pseudomyxoma peritonei].
Lu YY; Guo AT; Liu AJ; Shi HY
Zhonghua Fu Chan Ke Za Zhi; 2013 Aug; 48(8):595-601. PubMed ID: 24199925
[TBL] [Abstract][Full Text] [Related]
13. Pseudomyxoma Peritonei of Extra-Appendiceal Origin: A Comparative Study.
Baratti D; Kusamura S; Milione M; Pietrantonio F; Caporale M; Guaglio M; Deraco M
Ann Surg Oncol; 2016 Dec; 23(13):4222-4230. PubMed ID: 27352203
[TBL] [Abstract][Full Text] [Related]
14. Perioperative safety after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal origin: Experience on 254 patients from a single center.
Li XB; Ma R; Ji ZH; Lin YL; Zhang J; Yang ZR; Chen LF; Yan FC; Li Y
Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):600-606. PubMed ID: 31973925
[TBL] [Abstract][Full Text] [Related]
15. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei of appendicular and extra-appendicular origin.
Delhorme JB; Severac F; Averous G; Glehen O; Passot G; Bakrin N; Marchal F; Pocard M; Lo Dico R; Eveno C; Carrere S; Sgarbura O; Quenet F; Ferron G; Goéré D; Brigand C;
Br J Surg; 2018 May; 105(6):668-676. PubMed ID: 29412465
[TBL] [Abstract][Full Text] [Related]
16. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
Baratti D; Kusamura S; Nonaka D; Langer M; Andreola S; Favaro M; Gavazzi C; Laterza B; Deraco M
Ann Surg Oncol; 2008 Feb; 15(2):526-34. PubMed ID: 18043976
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of CEA, Ki67 and p53 in pseudomyxoma peritonei of appendiceal origin.
Yan F; Shi F; Li X; Chang H; Jin M; Li Y
J Int Med Res; 2021 Jun; 49(6):3000605211022297. PubMed ID: 34187207
[TBL] [Abstract][Full Text] [Related]
18. Serum and ascites tumor markers in the diagnostic and prognostic prediction for appendiceal pseudomyxoma peritonei.
Wang B; Ma R; Rao B; Xu H
BMC Cancer; 2023 Jan; 23(1):90. PubMed ID: 36703100
[TBL] [Abstract][Full Text] [Related]
19. Twenty-years' experience with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for pseudomyxoma peritonei (PMP).
Papantoni E; Ntatsis K; Kyziridis D; Kalakonas A; Hristakis C; Tentes AA
J BUON; 2021; 26(4):1647-1652. PubMed ID: 34565031
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Baratti D; Kusamura S; Martinetti A; Seregni E; Laterza B; Oliva DG; Deraco M
Ann Surg Oncol; 2007 Aug; 14(8):2300-8. PubMed ID: 17510772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
